Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Deconvolution of pro- and antiviral genomic responses in Zika virus-infected and bystander macrophages.

Carlin AF, Vizcarra EA, Branche E, Viramontes KM, Suarez-Amaran L, Ley K, Heinz S, Benner C, Shresta S, Glass CK.

Proc Natl Acad Sci U S A. 2018 Sep 11. pii: 201807690. doi: 10.1073/pnas.1807690115. [Epub ahead of print]

2.

Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy.

Regla-Nava JA, Elong Ngono A, Viramontes KM, Huynh AT, Wang YT, Nguyen AT, Salgado R, Mamidi A, Kim K, Diamond MS, Shresta S.

Nat Commun. 2018 Aug 2;9(1):3042. doi: 10.1038/s41467-018-05458-0.

3.

Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection.

Branche E, Tang WW, Viramontes KM, Young MP, Sheets N, Joo Y, Nguyen AT, Shresta S.

Antiviral Res. 2018 Jul 30;158:1-7. doi: 10.1016/j.antiviral.2018.07.022. [Epub ahead of print]

PMID:
30071205
4.

Author Correction: Blocking Zika virus vertical transmission.

Mesci P, Macia A, Moore SM, Shiryaev SA, Pinto A, Huang CT, Tejwani L, Fernandes IR, Suarez NA, Kolar MJ, Montefusco S, Rosenberg SC, Herai RH, Cugola FR, Russo FB, Sheets N, Saghatelian A, Shresta S, Momper JD, Siqueira-Neto JL, Corbett KD, Beltrão-Braga PCB, Terskikh AV, Muotri AR.

Sci Rep. 2018 Jun 5;8(1):8794. doi: 10.1038/s41598-018-26959-4.

5.

Blocking Zika virus vertical transmission.

Mesci P, Macia A, Moore SM, Shiryaev SA, Pinto A, Huang CT, Tejwani L, Fernandes IR, Suarez NA, Kolar MJ, Montefusco S, Rosenberg SC, Herai RH, Cugola FR, Russo FB, Sheets N, Saghatelian A, Shresta S, Momper JD, Siqueira-Neto JL, Corbett KD, Beltrão-Braga PCB, Terskikh AV, Muotri AR.

Sci Rep. 2018 Jan 19;8(1):1218. doi: 10.1038/s41598-018-19526-4. Erratum in: Sci Rep. 2018 Jun 5;8(1):8794.

6.

Development of Zika Virus Vaccines.

Makhluf H, Shresta S.

Vaccines (Basel). 2018 Jan 18;6(1). pii: E7. doi: 10.3390/vaccines6010007. Review.

7.

Immune Response to Dengue and Zika.

Ngono AE, Shresta S.

Annu Rev Immunol. 2018 Apr 26;36:279-308. doi: 10.1146/annurev-immunol-042617-053142. Epub 2018 Jan 18.

PMID:
29345964
8.

Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis.

Shiryaev SA, Mesci P, Pinto A, Fernandes I, Sheets N, Shresta S, Farhy C, Huang CT, Strongin AY, Muotri AR, Terskikh AV.

Sci Rep. 2017 Nov 17;7(1):15771. doi: 10.1038/s41598-017-15467-6.

9.

T Cell Immunity to Zika and Dengue Viral Infections.

Wen J, Shresta S.

J Interferon Cytokine Res. 2017 Nov;37(11):475-479. doi: 10.1089/jir.2017.0106. Review.

PMID:
29135369
10.

Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge.

Wen J, Elong Ngono A, Regla-Nava JA, Kim K, Gorman MJ, Diamond MS, Shresta S.

Nat Commun. 2017 Nov 13;8(1):1459. doi: 10.1038/s41467-017-01669-z.

11.

An IRF-3-, IRF-5-, and IRF-7-Independent Pathway of Dengue Viral Resistance Utilizes IRF-1 to Stimulate Type I and II Interferon Responses.

Carlin AF, Plummer EM, Vizcarra EA, Sheets N, Joo Y, Tang W, Day J, Greenbaum J, Glass CK, Diamond MS, Shresta S.

Cell Rep. 2017 Nov 7;21(6):1600-1612. doi: 10.1016/j.celrep.2017.10.054.

12.

ADE-ing and Abetting Zika.

Wen J, Shresta S.

Cell Host Microbe. 2017 May 10;21(5):557-558. doi: 10.1016/j.chom.2017.04.006.

13.

Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists.

Shiryaev SA, Farhy C, Pinto A, Huang CT, Simonetti N, Elong Ngono A, Dewing A, Shresta S, Pinkerton AB, Cieplak P, Strongin AY, Terskikh AV.

Antiviral Res. 2017 Jul;143:218-229. doi: 10.1016/j.antiviral.2017.04.015. Epub 2017 Apr 29.

14.

Modified mRNA Vaccines Protect against Zika Virus Infection.

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS.

Cell. 2017 Mar 23;169(1):176. doi: 10.1016/j.cell.2017.03.016. No abstract available.

15.

Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells.

Wen J, Tang WW, Sheets N, Ellison J, Sette A, Kim K, Shresta S.

Nat Microbiol. 2017 Mar 13;2:17036. doi: 10.1038/nmicrobiol.2017.36.

16.

Modified mRNA Vaccines Protect against Zika Virus Infection.

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS.

Cell. 2017 Mar 9;168(6):1114-1125.e10. doi: 10.1016/j.cell.2017.02.017. Epub 2017 Feb 17. Erratum in: Cell. 2017 Mar 23;169(1):176.

17.

Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice.

Elong Ngono A, Vizcarra EA, Tang WW, Sheets N, Joo Y, Kim K, Gorman MJ, Diamond MS, Shresta S.

Cell Host Microbe. 2017 Jan 11;21(1):35-46. doi: 10.1016/j.chom.2016.12.010.

18.

A Mouse Model of Zika Virus Sexual Transmission and Vaginal Viral Replication.

Tang WW, Young MP, Mamidi A, Regla-Nava JA, Kim K, Shresta S.

Cell Rep. 2016 Dec 20;17(12):3091-3098. doi: 10.1016/j.celrep.2016.11.070.

19.

The Neurobiology of Zika Virus.

Li H, Saucedo-Cuevas L, Shresta S, Gleeson JG.

Neuron. 2016 Dec 7;92(5):949-958. doi: 10.1016/j.neuron.2016.11.031. Review.

20.

Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection.

Elong Ngono A, Chen HW, Tang WW, Joo Y, King K, Weiskopf D, Sidney J, Sette A, Shresta S.

EBioMedicine. 2016 Nov;13:284-293. doi: 10.1016/j.ebiom.2016.10.006. Epub 2016 Oct 7.

21.

Zika Virus Infects Neural Progenitors in the Adult Mouse Brain and Alters Proliferation.

Li H, Saucedo-Cuevas L, Regla-Nava JA, Chai G, Sheets N, Tang W, Terskikh AV, Shresta S, Gleeson JG.

Cell Stem Cell. 2016 Nov 3;19(5):593-598. doi: 10.1016/j.stem.2016.08.005. Epub 2016 Aug 18.

22.

Novel strategies for discovering inhibitors of Dengue and Zika fever.

Makhluf H, Kim K, Shresta S.

Expert Opin Drug Discov. 2016 Oct;11(10):921-3. doi: 10.1080/17460441.2016.1212013. Epub 2016 Jul 21. No abstract available.

PMID:
27401601
23.

Neuroteratogenic Viruses and Lessons for Zika Virus Models.

Kim K, Shresta S.

Trends Microbiol. 2016 Aug;24(8):622-636. doi: 10.1016/j.tim.2016.06.002. Epub 2016 Jul 4. Review.

PMID:
27387029
24.

Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4.

Warfield KL, Plummer EM, Sayce AC, Alonzi DS, Tang W, Tyrrell BE, Hill ML, Caputo AT, Killingbeck SS, Beatty PR, Harris E, Iwaki R, Kinami K, Ide D, Kiappes JL, Kato A, Buck MD, King K, Eddy W, Khaliq M, Sampath A, Treston AM, Dwek RA, Enterlein SG, Miller JL, Zitzmann N, Ramstedt U, Shresta S.

Antiviral Res. 2016 May;129:93-98. doi: 10.1016/j.antiviral.2016.03.001. Epub 2016 Mar 3.

25.

Innate Antiviral Immunity against Dengue Virus.

Makhluf H, Shresta S.

Crit Rev Immunol. 2015;35(3):253-60. Review.

PMID:
26559229
26.

Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.

Pinto AK, Brien JD, Lam CY, Johnson S, Chiang C, Hiscott J, Sarathy VV, Barrett AD, Shresta S, Diamond MS.

MBio. 2015 Sep 15;6(5):e01316-15. doi: 10.1128/mBio.01316-15.

27.

Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy.

Flingai S, Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE, Sardesai NY, Muthumani K, Weiner DB.

Sci Rep. 2015 Jul 29;5:12616. doi: 10.1038/srep12616.

28.

Different STAT Transcription Complexes Drive Early and Delayed Responses to Type I IFNs.

Abdul-Sater AA, Majoros A, Plumlee CR, Perry S, Gu AD, Lee C, Shresta S, Decker T, Schindler C.

J Immunol. 2015 Jul 1;195(1):210-216. doi: 10.4049/jimmunol.1401139. Epub 2015 May 27.

29.

Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models.

Tang WW, Grewal R, Shresta S.

Curr Opin Virol. 2015 Aug;13:61-6. doi: 10.1016/j.coviro.2015.04.007. Epub 2015 May 23. Review.

PMID:
26001278
30.

A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue).

Warfield KL, Plummer E, Alonzi DS, Wolfe GW, Sampath A, Nguyen T, Butters TD, Enterlein SG, Stavale EJ, Shresta S, Ramstedt U.

Viruses. 2015 May 13;7(5):2404-27. doi: 10.3390/v7052404.

31.

CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.

Zellweger RM, Tang WW, Eddy WE, King K, Sanchez MC, Shresta S.

J Virol. 2015 Jun;89(12):6494-505. doi: 10.1128/JVI.00036-15. Epub 2015 Apr 8.

32.

Dengue Virus Evolution under a Host-Targeted Antiviral.

Plummer E, Buck MD, Sanchez M, Greenbaum JA, Turner J, Grewal R, Klose B, Sampath A, Warfield KL, Peters B, Ramstedt U, Shresta S.

J Virol. 2015 May;89(10):5592-601. doi: 10.1128/JVI.00028-15. Epub 2015 Mar 11.

33.

CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice.

Zellweger RM, Eddy WE, Tang WW, Miller R, Shresta S.

J Immunol. 2014 Oct 15;193(8):4117-24. doi: 10.4049/jimmunol.1401597. Epub 2014 Sep 12.

34.

Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.

Weiskopf D, Angelo MA, Sidney J, Peters B, Shresta S, Sette A.

J Virol. 2014 Oct;88(19):11383-94. doi: 10.1128/JVI.01108-14. Epub 2014 Jul 23.

35.

Mouse models to study dengue virus immunology and pathogenesis.

Zellweger RM, Shresta S.

Front Immunol. 2014 Apr 10;5:151. doi: 10.3389/fimmu.2014.00151. eCollection 2014. Review.

36.

Animal models in dengue.

Plummer E, Shresta S.

Methods Mol Biol. 2014;1138:377-90. doi: 10.1007/978-1-4939-0348-1_23.

PMID:
24696349
37.

Mouse models for dengue vaccines and antivirals.

Plummer EM, Shresta S.

J Immunol Methods. 2014 Aug;410:34-8. doi: 10.1016/j.jim.2014.01.001. Epub 2014 Jan 15.

PMID:
24440090
38.

Dengue virus vaccine development.

Yauch LE, Shresta S.

Adv Virus Res. 2014;88:315-72. doi: 10.1016/B978-0-12-800098-4.00007-6. Review.

PMID:
24373316
39.

Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.

Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S.

PLoS Pathog. 2013 Oct;9(10):e1003723. doi: 10.1371/journal.ppat.1003723. Epub 2013 Oct 31.

40.

The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus.

Chen HW, King K, Tu J, Sanchez M, Luster AD, Shresta S.

J Immunol. 2013 Oct 15;191(8):4194-201. doi: 10.4049/jimmunol.1300799. Epub 2013 Sep 16.

41.

Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.

Chen HW, Cheng JX, Liu MT, King K, Peng JY, Zhang XQ, Wang CH, Shresta S, Schooley RT, Liu YT.

Antiviral Res. 2013 Sep;99(3):371-82. doi: 10.1016/j.antiviral.2013.06.014. Epub 2013 Jun 29.

42.

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells.

Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, Mattia KA, Doranz BJ, Grey HM, Shresta S, Peters B, Sette A.

Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53. doi: 10.1073/pnas.1305227110. Epub 2013 Apr 11.

43.

An iminosugar with potent inhibition of dengue virus infection in vivo.

Perry ST, Buck MD, Plummer EM, Penmasta RA, Batra H, Stavale EJ, Warfield KL, Dwek RA, Butters TD, Alonzi DS, Lada SM, King K, Klose B, Ramstedt U, Shresta S.

Antiviral Res. 2013 Apr;98(1):35-43. doi: 10.1016/j.antiviral.2013.01.004. Epub 2013 Jan 31.

PMID:
23376501
44.

Tracking the evolution of dengue virus strains D2S10 and D2S20 by 454 pyrosequencing.

Makhluf H, Buck MD, King K, Perry ST, Henn MR, Shresta S.

PLoS One. 2013;8(1):e54220. doi: 10.1371/journal.pone.0054220. Epub 2013 Jan 14.

45.

Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice.

Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM, Yauch LE, Lada SM, Shresta S.

J Virol. 2012 Dec;86(23):12561-70. doi: 10.1128/JVI.06743-11. Epub 2012 Sep 12.

46.

Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice.

Prestwood TR, May MM, Plummer EM, Morar MM, Yauch LE, Shresta S.

J Virol. 2012 Nov;86(22):12138-47. doi: 10.1128/JVI.00375-12. Epub 2012 Aug 29.

47.

Role of complement in dengue virus infection: protection or pathogenesis?

Shresta S.

MBio. 2012 Feb 7;3(1). pii: e00003-12. doi: 10.1128/mBio.00003-12. Print 2012.

48.

Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design.

Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, Kolla RV, De Silva AD, de Silva AM, Grey H, Peters B, Shresta S, Sette A.

J Immunol. 2011 Oct 15;187(8):4268-79. doi: 10.4049/jimmunol.1101970. Epub 2011 Sep 14.

49.

Better late than never: antivirals for dengue.

Perry ST, Buck MD, Shresta S.

Expert Rev Anti Infect Ther. 2011 Jul;9(7):755-7. doi: 10.1586/eri.11.68. No abstract available.

PMID:
21810045
50.

Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.

Stein DA, Perry ST, Buck MD, Oehmen CS, Fischer MA, Poore E, Smith JL, Lancaster AM, Hirsch AJ, Slifka MK, Nelson JA, Shresta S, Früh K.

J Virol. 2011 Oct;85(19):10154-66. doi: 10.1128/JVI.05298-11. Epub 2011 Jul 27.

Supplemental Content

Loading ...
Support Center